BRAF突变型儿童胶质瘤细胞在MAPK抑制剂停药后的反弹生长与MAPK再激活及招募微胶质细胞的细胞因子分泌相关
本研究利用四种患者来源的儿童胶质瘤模型体外模拟MAPK抑制剂停药后的反弹生长,仅BRAFV600E驱动模型(BT-40,伴CDKN2A/B缺失)出现反弹。多组学及体内验证显示停药后MAPK通路快速再激活,且给药期间及停药早期细胞因子(CCL2、CX3CL1、CXCL10、CCL7)分泌增加,可体外招募微胶质细胞。
要点
- 仅BRAFV600E驱动伴CDKN2A/B缺失的BT-40模型在MAPKi停药后出现反弹生长。
- 停药后MAPK通路在体外和体内均快速再激活。
- MAPKi处理诱导细胞因子分泌增加,可体外招募微胶质细胞。
核心结论
- MAPKi停药后MAPK快速再激活是肿瘤细胞内在的反弹驱动机制。
- 微胶质细胞招募细胞因子分泌增加可能在治疗反应和停药后反弹生长中起作用,需进一步评估。
研究设计与样本
- 研究采用四种患者来源的儿童胶质瘤模型,基于活细胞计数体外模拟MAPKi治疗及停药后的反弹生长。
- 生成多组学数据集(RNA测序和基于LC-MS/MS的磷酸化/蛋白质组学)探究反弹驱动机制。
- 体外验证后,利用BT-40原位异种移植模型进行体内验证。
主要发现
- 四种测试模型中,仅BRAFV600E驱动模型(BT-40,伴额外CDKN2A/B缺失)在MAPKi停药后出现反弹生长。
- BT-40模型体外MAPKi停药后MAPK通路快速再激活,体内亦得到证实。
- 体外观察到关键MAPK分子在转录水平(如FOS)和磷酸化水平(如pMEK)的短暂过度激活。
- MAPKi处理时细胞因子(CCL2、CX3CL1、CXCL10和CCL7)表达和分泌增加,停药早期维持。
- 细胞因子表达增加无肿瘤细胞内在效应,但条件培养基中这些细胞因子可体外增加微胶质细胞招募。
局限性
- 原文结论指出细胞因子分泌增加在治疗反应和停药后反弹生长中的作用需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with pediatric low-grade gliomas (pLGGs), the most common primary brain tumors in children, can often benefit from MAPK inhibitor (MAPKi) treatment. However, rapid tumor regrowth, also referred to as rebound growth, may occur once treatment is stopped, constituting a significant clinical challenge. METHODS: Four patient-derived pediatric glioma models were investigated to model rebound growth in vitro based on viable cell counts in response to MAPKi treatment and withdrawal. A multi-omics dataset (RNA sequencing and LC-MS/MS based phospho-/proteomics) was generated to investigate possible rebound-driving mechanisms. Following in vitro validation, putative rebound-driving mechanisms were validated in vivo using the BT-40 orthotopic xenograft model. RESULTS: Of the tested models, only a BRAFV600E-driven model (BT-40, with additional CDKN2A/Bdel) showed rebound growth upon MAPKi withdrawal. Using this model, we identified a rapid reactivation of the MAPK pathway upon MAPKi withdrawal in vitro, also confirmed in vivo. Furthermore, transient overactivation of key MAPK molecules at transcriptional (e.g. FOS) and phosphorylation (e.g. pMEK) levels, was observed in vitro. Additionally, we detected increased expression and secretion of cytokines (CCL2, CX3CL1, CXCL10 and CCL7) upon MAPKi treatment, maintained during early withdrawal. While increased cytokine expression did not have tumor cell intrinsic effects, presence of these cytokines in conditioned media led to increased attraction of microglia cells in vitro. CONCLUSION: Taken together, these data indicate rapid MAPK reactivation upon MAPKi withdrawal as a tumor cell intrinsic rebound-driving mechanism. Furthermore, increased secretion of microglia-recruiting cytokines may play a role in treatment response and rebound growth upon withdrawal, warranting further evaluation.
引用
- Kocher D, Cao L, Guiho R, et al. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines. J Neurooncol. 2024. PMID: 38630384. doi:10.1007/s11060-024-04672-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。